or FDPS inhibitor provides a rational approach for reducing cholesterol synthesis while preventing non-sterol isoprenoid depletion.
INTRODUCTION
The mevalonate pathway ( Fig. 1) is responsible for production of the core fivecarbon isoprenoid isopentenyl diphosphate (IPP) from 3-hydroxy-3-methylglutarylcoenzyme A (HMG-CoA) (1) . HMG-CoA is first reduced to mevalonate by HMG-CoA reductase (HMGCR). Through a short series of enzymatic reactions, mevalonate is then converted into IPP. Both IPP and its isomer dimethylallyl diphosphate (DMAPP) are utilized by farnesyl diphosphate synthase (FDPS) to generate the fifteen-carbon farnesyl diphosphate (FPP), which resides at the major branch point of the mevalonate pathway.
Addition of an isoprene unit from IPP to FPP yields geranylgeranyl diphosphate (GGPP), a process mediated by the enzyme geranylgeranyl diphosphate synthase (GGDPS). The isoprene moiety of FPP or GGPP can be post translationally adducted onto proteins by protein farnesyltransferase or geranylgeranyltransferases, respectively, in a process collectively referred to as protein prenylation. In the first committed step of de novo cholesterol synthesis, two molecules of FPP are condensed in a head-to-head orientation to first form pre-squalene diphosphate and subsequently squalene. This reaction is catalyzed by the enzyme squalene synthase (SQS), which is encoded for by the gene farnesyl diphosphate farnesyl transferase 1 (FDFT1).
Inhibition of mevalonate pathway targets has yielded multiple drugs with clinical success. Statins (e.g., lovastatin and atorvastatin) are a class of drugs commonly prescribed to reduce cholesterol levels. Statins inhibit HMGCR (2) , which is the rate limiting step of cholesterol biosynthesis (3) . This leads to upregulation of the low density lipoprotein (LDL) receptor (LDLR) in the liver and clearance of cholesterol-containing LDL particles from the bloodstream. The use of statin drugs is prevalent because elevated total cholesterol and LDL levels are major risk factors for coronary heart disease (4) . While the statins are used abundantly and effectively, there are various reasons for developing novel inhibitors of cholesterol biosynthesis. There can be side-effects associated with statin use such as myopathy and hepatotoxicity (5) , which are commonly speculated to be due to the depletion of non-sterol components of the mevalonate pathway (6) . Furthermore, statin use does not always reduce LDL to desired levels (7), which is particularly important as lower LDL target levels are suggested for some patients (8) (9) (10) .
Inhibition of SQS has attracted much interest as a pharmacological target, and various compounds have been identified as inhibitors (11, 12) . Lapaquistat (TAK-475, Takeda) progressed to phase III clinical trials, but studies were discontinued after the U.S. Food and Drug Administration recommended suspension of studies with high dose (100 mg/kg) mono-therapy due to hepatotoxicity manifested as elevated levels of liver transaminases (12) . It is currently unknown whether this was due to an enzyme inhibitory class effect, or if it was specific to the drug. Inhibition of SQS can result in the accumulation of both FPP and FPP metabolites, such as farnesol-derived dicarboxylic acids (13) , which could be responsible for the possible hepatotoxicity with the high-dose monotherapy of lapaquistat. Farnesol itself can also be pro-apoptotic at high concentrations (14) . Other reported results appeared promising with lapaquistat, with cholesterol levels decreased in monotherapy treatment. Moreover, the combination therapy of lapaquistat with statins showed additional LDL reduction compared to statins alone (12) . Also of interest, lapaquistat's active metabolite T-91485 was capable of preventing statin-induced myotoxicity in a human skeletal muscle cell model (15 Similarly, lapaquistat was able to prevent statin-induced myotoxicity in a guinea pig model (16) . In addition to the expected cholesterol depletion, other SQS inhibitors have shown the potential for added benefits due to decreased triglyceride biosynthesis (17) , likely resulting from a farnesol-induced mechanism (18) .
Nitrogenous bisphosphonates (NBPs; e.g., zoledronate, alendronate) are a second class of clinical drugs targeting the mevalonate pathway, and are used for treatment of bone-related disorders such as osteoporosis. NBPs function by inhibition of FDPS, thus depleting cellular levels of FPP and other downstream isoprenoids (19) . Bisphosphonates may be regarded as analogs of diphosphates, in which the central bridging oxygen atom (P-O-P) has been replaced with a carbon (P-C-P). This results in increased metabolic stability and allows chemical functionalization of the bisphosphonate core. Furthermore, the P-C-P linkage combined with an α-hydroxy group facilitates bone targeting (20) .
Although these compounds have a high affinity for bone, there are also reports of decreased cholesterol levels with patients treated with nitrogenous bisphosphonates (21).
To our knowledge, the combination of an FDPS inhibitor with an SQS inhibitor has not been evaluated.
While various SQS inhibitors exist, relatively few are based on a bisphosphonate structure (22) , and their specificity for SQS relative to the prenylation arm of the mevalonate pathway has not been reported. Herein, we describe the synthesis and identification of novel bisphosphonates as potent inhibitors of SQS. A structure activity relationship is evaluated in the context of potency and specificity for these novel compounds. Emphasis is placed on the evaluation of a lead compound 5 ( 
EXPERIMENTAL PROCEDURES

Chemical synthesis
Preparation of compounds 1 (23) and 2 (24, 25) has been described, while compounds 3-5 were prepared as follows. In short, geranyl acetate was oxidized with SeO 2 under reported literature procedures (26) (Fig. 3) . The newly formed hydroxyl group was protected by reaction with 3,4-dihydro-2H-pyran and the acetate group was removed (27) . The resulting product then was split and carried forward in three divergent directions. The 2-tetrahydropyranyl (THP) protecting group of alcohol 10 was subjected to copper-mediated Grignard displacement (24, 25, 28) with the corresponding biphenyl Grignard reagents to provide independently the ortho, meta and para analogues 11, 12, and 13 respectively. Standard conversion of the free hydroxyl group to the allylic bromide was performed using PBr 3 . After workup, the bromides were used without further purification in the subsequent alkylation of tetraethyl methylenebisphosphonate (29) . The resulting phosphonate esters 17, 18, and 19 were hydrolyzed to their corresponding salts (3, 4, and 5, respectively) under standard McKenna procedures (30) .
All bisphosphonate salts were dissolved in water prior to use for biological studies.
Detailed experimental and characterization data is provided in the supplemental section.
Protein purification
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A plasmid containing glutathione-S-transferase tagged human squalene synthase (EX-C0605-B03) was obtained from Genecopoeia (Rockville, MD). The plasmid was transformed into BL21 (DE3) Escherichia coli and expressed using 0.1 mM isopropyl ß-D-1-thiogalactopyranoside (IPTG) overnight at room temperature. Following lysis using lysozyme, 1.5% sarkosyl was added to increase protein solubility. Tagged protein was purified using glutathione agarose beads (Sigma; St. Louis, MO) according to the manufacturer's protocol.
SQS enzyme assays
Enzyme assays were performed in 20 µL reactions containing 50 mM phosphate Louis, MO) and 2 mM NADPH. Inhibitors were added with enzyme and incubated for 10 min at 37 °C. Substrate was then added and reactions were incubated for 10 min at 37 °C. Reactions were stopped by addition of 300 µl 1 mM EDTA and then 1 ml ice cold petroleum ether was added. After freezing the lower aqueous phase, the upper phase containing the products was transferred to a scintillation vial containing liquid scintillation fluid, and radioactivity was quantitated using a Beckman liquid scintillation counter. Data was analyzed using Prism Graphpad software. Louis, MO), and 10% fetal bovine serum.
Cell culture
Western blot analysis
Protein concentrations were determined by the bicinchoninic acid method (BCA).
Proteins were resolved on 12 or 15% gels and transferred to polyvinylidene difluoride membranes via electrophoresis. Blocking was performed in 5% non-fat dry milk for 45 minutes, after which primary and secondary antibodies were added sequentially for 1 hour each at 37 o C. Proteins were visualized using enhanced chemiluminescence detection.
Rap1a and α-tubulin antibodies were acquired from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA) and anti-pan-Ras was acquired from
InterBiotechnology (Tokyo, Japan).
Cholesterol biosynthesis assay
Cells were plated in 12 well plates and grown to near confluency. Compounds were added for one hour followed by the addition of 1 µCi of 1- hours. Cells were harvested using trypsin and lipids were extracted using the Bligh and Dyer method (31) . Chloroform extracts were dried, resuspended in a 30 µl of chloroform and loaded on S-60 silica TLC plates. TLC was performed using an eluting solvent system of toluene and isopropyl ether (1:1) as the mobile phase. Plates were stained with iodide to determine the location of a cholesterol standard. Regions corresponding to cholesterol were excised from the plate and radioactivity was quantified using a liquid scintillation counter.
Measurement of FPP and GGPP levels
Both FPP and GGPP levels were determined as reported (32) . Briefly, FPP and GGPP were extracted from cells and incorporated into fluorescently labeled CAAX peptides by FTase and GGTase, which were then quantified by fluorescent detection on an HPLC. Levels were normalized to total protein as measured by BCA assay.
MTT Assay
The MTT assay measures the activity of enzymes that reduce the MTT substrate within metabolically active cells and is commonly used as a measure of cell viability.
Cells were allowed to adhere in 24-well plates and grown until approximately 50%
confluent. Cells were treated with indicated compounds and incubated for 45 hours, followed by addition of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT; EMD Chemicals; La Jolla, CA) and incubation for an additional 3 hours. MTT stop solution (HCl, triton X-100, and isopropyl alcohol) was then added and plates were gently agitated at 37 °C overnight. Absorbance was measured at 540 nm with a reference wavelength at 650 nm.
Real-time quantitative PCR
HepG2 cells were allowed to adhere in 6-well plates and grown until approximately 50% confluent. Cells were then washed with PBS and the cells were equilibrated in media containing 10% lipoprotein deficient serum (LPDS) for 24 hours.
Cells were then treated for 24 hours in media containing 10% LPDS with indicated compounds. Total RNA was isolated using Qiashredders and RNase easy mini kit (Qiagen), with inclusion of a DNase step as recommended. cDNA was made from 1 µg of RNA by reverse-transcription using the iScript DNA Synthesis Kit (Bio-Rad 
RESULTS
In vitro inhibition of recombinant SQS
A screen of in-house compounds was performed to identify in vitro inhibitors of SQS. A small panel of compounds (1, 2, 3, 4 and 5) was selected for further study of their inhibitory activity (Fig. 2) . These compounds were synthesized as described in the Experimental Procedures. Dose response curves were used to determine the concentration of compound required to inhibit 50% of SQS activity (IC 50 value, Table 1 ).
Geranyl bisphosphonate (1) 
Effect of compound 5 and lovastatin on FPP and GGPP levels
We next measured the FPP and GGPP levels from HepG2 cells in response to treatment with either compound 5 or lovastatin alone and in combination for 24 hours. In 
